Endeavor Biomedicines Inc

Endeavor Biomedicines Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative medicines aimed at delivering transformational clinical benefits to patients with life-threatening diseases. Their leading investigational candidates include ENV101, an inhibitor of the Hedgehog signaling pathway for treating fibrotic lung diseases, and ENV501, a targeted antibody-drug conjugate for HER3-positive solid tumors.

The company's mission is to disrupt disease progression and restore hope by precisely targeting the root causes of illnesses, with a vibrant culture that reflects their commitment to improving patient outcomes. Endeavor Biomedicines is dedicated to developing groundbreaking therapies that not only slow disease progression but also aim to reverse the trajectory of relentless conditions.

Generated from the website